Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Evaluation of the Onset and Duration of Action of Cetirizine 0.24% Ophthalmic Solution (Formula AFH-002) Compared to Vehicle (Formula AFH-001) in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis

Next Previous
Search
Trial Profile

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Evaluation of the Onset and Duration of Action of Cetirizine 0.24% Ophthalmic Solution (Formula AFH-002) Compared to Vehicle (Formula AFH-001) in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetirizine (Primary)
  • Indications Allergic conjunctivitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Aciex Therapeutics

    • Most Recent Events

    • 31 May 2017 According to a Nicox media release, the US FDA has approved the New Drug Application (NDA) for ZERVIATE1 (cetirizine ophthalmic solution 0.24%; formerly AC-170) for the treatment of ocular itching associated with allergic conjunctivitis. The approval was based on this and two other trials using the conjunctival antigen challenge (Ora-CAC model of allergic conjunctivitis).
    • 22 Oct 2015 According to a Nicox media release, the company expects to submit a New Drug Application for cetirizine [AC-170] by the first half of 2016.
    • 04 Jun 2015 According to a Nicox media release, New Drug Application submission for cetirizine [AC-170] remains on track. Nicox's objective is to obtain FDA approval by the end of 2016.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top